- Trials with a EudraCT protocol (210)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
210 result(s) found for: 4 mg/kg every 8 weeks.
Displaying page 1 of 11.
EudraCT Number: 2011-005682-20 | Sponsor Protocol Number: MOR-008 | Start Date*: 2012-06-19 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) | |||||||||||||
Medical condition: Mucopolysaccharidosis Type IVA | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024540-15 | Sponsor Protocol Number: C38072/3085 | Start Date*: 2011-07-20 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: An Open-Label Extension Study to evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma who completed a prior Cephalon-sponsored Stu... | |||||||||||||
Medical condition: Treatment for patients with eosinophilic asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) SE (Completed) CZ (Completed) GR (Completed) HU (Completed) NL (Completed) DK (Prematurely Ended) PL (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001762-42 | Sponsor Protocol Number: 4658-402 | Start Date*: 2020-04-03 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular ... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: IE (Restarted) GB (GB - no longer in EU/EEA) FR (Ongoing) ES (Ongoing) SE (Prematurely Ended) DE (Restarted) DK (Restarted) NL (Ongoing) PL (Ongoing) GR (Ongoing) NO (Ongoing) HU (Ongoing) CZ (Ongoing) SI (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003197-84 | Sponsor Protocol Number: MOR-007 | Start Date*: 2011-11-22 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age with Mucopolysaccharidosis IVA (Morquio A Syndrome) | |||||||||||||
Medical condition: Mucopolysaccharidosis Type IVA | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003123-37 | Sponsor Protocol Number: | Start Date*: 2006-10-12 |
Sponsor Name:University Hospital Sint Radboud | ||
Full Title: Treatment with high dose Methotrexate in patients with eosinophilic fasciitis | ||
Medical condition: Eosinophilic fasciitis (EF) is a skin disorder involving the deep fascia, resulting in pain and swelling of extremities, cutaneous induration and joint contractures. Most patients require therapy. ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000601-77 | Sponsor Protocol Number: 5051-201 | Start Date*: 2019-12-11 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, then Dose Expansion, in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: IE (Prematurely Ended) ES (Temporarily Halted) GB (GB - no longer in EU/EEA) BE (Ongoing) NL (Restarted) DE (Restarted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020199-45 | Sponsor Protocol Number: MOR-005 | Start Date*: 2011-06-08 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) | |||||||||||||
Medical condition: Mucopolysaccharidosis Type IVA | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) IT (Completed) PT (Completed) DK (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020198-18 | Sponsor Protocol Number: MOR-004 | Start Date*: 2010-12-30 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/week and 2.0 mg/kg/every other week BMN 110 in Patients with M... | |||||||||||||
Medical condition: Mucopolysaccharidosis Type IVA | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) FR (Ongoing) DE (Completed) PT (Completed) IT (Completed) NO (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004432-38 | Sponsor Protocol Number: CINC424D2301 | Start Date*: 2017-10-11 | ||||||||||||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||||||||||||
Full Title: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogeneic stem cel... | ||||||||||||||||||||||||||||
Medical condition: corticosteroid refractory chronic Graft vs Host Disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) AT (Completed) ES (Ongoing) BE (Completed) DK (Completed) NL (Completed) IT (Ongoing) FR (Ongoing) PT (Completed) HU (Completed) PL (Completed) BG (Completed) NO (Completed) GR (Completed) RO (Ongoing) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001790-41 | Sponsor Protocol Number: AB11002 | Start Date*: 2013-04-10 | |||||||||||
Sponsor Name:AB Science | |||||||||||||
Full Title: A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointesti... | |||||||||||||
Medical condition: Gastrointestinal stromal tumor resistant to imatinib | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) ES (Ongoing) NL (Ongoing) DE (Prohibited by CA) BE (Prematurely Ended) AT (Ongoing) GB (GB - no longer in EU/EEA) GR (Prematurely Ended) IT (Suspended by CA) CY (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003558-26 | Sponsor Protocol Number: ABX464-103 | Start Date*: 2019-12-10 | |||||||||||
Sponsor Name:ABIVAX | |||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel group, multiple dose, induction study to evaluate the safety, tolerability and optimal dose of ABX464 compared with placebo in patients with... | |||||||||||||
Medical condition: Moderate to Severe Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) SI (Completed) CZ (Completed) DE (Completed) SK (Completed) HU (Completed) PL (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003947-12 | Sponsor Protocol Number: Treg003 | Start Date*: 2017-06-19 | |||||||||||
Sponsor Name:Freistaat Bayern represented by University of Regensburg represented by Kaufmännischer Direktor | |||||||||||||
Full Title: Treatment of steroid-resistant chronic graft-versus-host-disease with donor-derived regulatory T cells | |||||||||||||
Medical condition: Treatment of steroid-resistant chronic graft-versus-host disease with donor-derived regulatory T cells | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001429-30 | Sponsor Protocol Number: WA42294 | Start Date*: 2021-03-15 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) | |||||||||||||
Medical condition: Idiopathic pulmonary fibrosis (IPF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) CZ (Completed) DE (Prematurely Ended) SE (Prematurely Ended) GR (Prematurely Ended) HU (Completed) PT (Prematurely Ended) AT (Prematurely Ended) FI (Completed) NO (Completed) DK (Prematurely Ended) PL (Completed) NL (Completed) BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002957-67 | Sponsor Protocol Number: CA209-010 | Start Date*: 2011-11-23 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic T... | ||||||||||||||||||
Medical condition: Advanced/Metastatic renal cell carcinoma with a clear cell component | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001243-67 | Sponsor Protocol Number: CAIN457A2208 | Start Date*: 2011-07-01 | |||||||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||||||||||||
Full Title: An open-label proof-of-concept study with a double-masked, dose-ranging component to assess the effects of AIN457 in patients with noninfectious uveitis | |||||||||||||||||||||||
Medical condition: Intermediate, posterior or pan-uveitis of noninfectious origin | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000338-46 | Sponsor Protocol Number: D4191C00004 | Start Date*: 2015-06-17 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care... | ||||||||||||||||||
Medical condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) GR (Completed) HU (Completed) NL (Completed) CZ (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000791-38 | Sponsor Protocol Number: WA42293 | Start Date*: 2021-04-14 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | |||||||||||||
Medical condition: Idiopathic pulmonary fibrosis (IPF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) CZ (Completed) DE (Completed) HU (Completed) GR (Prematurely Ended) FI (Completed) PT (Prematurely Ended) NO (Completed) DK (Prematurely Ended) PL (Completed) NL (Completed) BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005703-33 | Sponsor Protocol Number: MOR-006 | Start Date*: 2012-06-19 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation | |||||||||||||
Medical condition: Mucopolysaccharidosis Type IVA | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003829-29 | Sponsor Protocol Number: EMR200637-002 | Start Date*: 2014-10-27 | |||||||||||
Sponsor Name:Symphogen A/S | |||||||||||||
Full Title: Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects with Metastatic Color... | |||||||||||||
Medical condition: Metastatic colorectal cancer with Acquired Resistance to Anti-EGFR Monoclonal Antibodies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) BE (Completed) AT (Completed) HU (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000073-21 | Sponsor Protocol Number: BH29992 | Start Date*: 2016-05-12 | |||||||||||
Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIA... | |||||||||||||
Medical condition: Hemophilia A with Inhibitors | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.